We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Epigenetic MGMT Test Enters Phase III Brain Cancer Study

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Epigenetic MGMT Test Enters Phase III Brain Cancer Study"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

MDxHealth's epigenetic MGMT test (PredictMDx(TM) for Glioblastoma) will be used to select patients to enroll in a randomized, multicenter phase III clinical study examining the addition of lomustine (also known as CCNU) to the current therapy of temozolomide/radiotherapy in MGMT methylated, newly diagnosed glioblastoma multiforme (GBM) patients, a severe form of brain cancer. The study, called CeTeG, will start recruiting patients this month and will last for approximately 2 years. Financial terms of the deal were not disclosed.